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INTRODUCTION
The genes of cancer/testis antigens (CTA) such as melanoma anti-
gen gene (MAGE) and synovial sarcoma on X chromosome (SSX)
are thought to be silent in normal adult tissues except testis. How-
ever, these genes are expressed at a high frequency in a large vari-
ety of cancer cells. Therefore, the corresponding transcripts rep-
resent attractive targets for cancer immunotherapy and cancer
diagnosis (1-4).
The MAGE A family consists of several subtypes, including
MAGE-1 to MAGE-12. During the past several years, many re-
searchers have studied the expression of individual MAGE A genes
for cancer diagnosis. However, the use of MAGE genes in the
detection of a small number of cancer cells by reverse transcrip-
tion-polymerase chain reaction (RT-PCR) has been limited by
the low expression frequency of individual MAGE genes in var-
ious cancer tissues. It has been reported that the probability of a
cancer cell expressing at least one MAGE gene is very high (5-
7). In order to improve the detection rate of MAGEgenes, we
have recently designed common primers that can bind simulta-
neously to the cDNA of MAGE-1, -2, -3, -4a, -4b, -5a, -5b and
-6 (MAGE 1-6). We also developed a MAGE 1-6 assay that can
simultaneously detect the transcripts of MAGE 1-6 (8).
The SSX gene family, which was originally identified as fusion
partners to the SYT gene in synovial sarcomas, consists of 9 sub-
type genes (SSX 1-9). The known SSX family members share high
homology at the protein and DNA level. Also, naturally occur-
ring serologic responses mounted by cancer patients against one
SSX family member cross-react with other members of the fam-
ily (9-11). The high level of homology between the subtypes at
the DNA and protein levels suggests that it may be possible to
design a common primer for the SSX family. In this study, we
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Original Articledesigned a common SSX primer, and developed an SSX 1-9 assay
that can detect cancer cells expressing at least one of the 9 SSX
genes by RT-nested PCR using the common SSX primers. 
MATERIALS AND METHODS
Cell culture
Thirty five cancer cell lines derived from stomach cancer (SNU
484, SNU 620, SNU 638, SNU 668), colon cancer (SNU C1, SNU
C4, SNU C5, HT29, HCT 116), head and neck cancer (AMC-
HN3, AMC-HN4, AMC-HN7), leukemia (U937, HL 60) cervi-
cal cancer (Caski, C4-II, ME-180, Hela, CUNC-6, SiHa), lung
cancer (NCI-H292, NCI-H522, NCI-H1703, A-549), prostate
cancer (PC 3, DU 145), hepatocellular carcinoma (HEPG2, SNU
182, SNU 354, SNU 387, SNU 398, SNU 423), kidney cancer
(HEK 293), breast cancer (MDA 231), and osteosarcoma (SAOS
2) were studied for the expression of SSX 1-9 genes. These can-
cer cell lines were grown in DMEM or RPMI1640 supplemented
with 10% FBS in a 5% CO2 incubator at 37℃. Then total RNA
was extracted with the trizol chloroform method. 
Cancer tissue and sputum specimens
The cancer tissue samples were obtained from 29 head and neck
cancer patients who were surgically treated at the Department of
Otolaryngology, School of Medicine, Kosin University, Busan,
Korea. The tissue samples were immediately frozen and kept at
-70℃. Then total RNA was extracted with the trizol chloroform
method.
Induced sputum samples were obtained from 18 patients with
head and neck cancer and 22 patients with benign pulmonary
diseases such as pneumonia, bronchitis, and tuberculosis. Induced
sputum was collected after inhalation of 100  g of Ventolin (Gl-
axoSmithKline, London, UK) and nebulization with 3% hyper-
tonic saline solution for 10 min. The induced sputum was mixed
with 10 mL of specimen protector (iC&G Co., Daegu, Korea)
and stored at -20℃until RNA isolation. The messenger RNA in
sputum was extracted using a sputum mRNA extraction kit
(iC&G Co.) according to the manufacturer’s instructions. Briefly,
after thawing the sputum that had been digested with the speci-
men protector, the undigested debris was removed by centrifu-
gation, and capture beads were then added to the liquefied super-
natants. After mixing the liquefied sputum and beads for 30 min
at room temperature, the beads were separated in a magnet rack
and washed 3 times with washing buffer. Messenger RNAs
attached to the beads were eluted with an elution buffer and
stored at -70℃until the reverse transcription reaction. 
MAGE 1-6 assay
Detection of transcripts of MAGE 1-6 gene was performed using
the Cancer Hunter kit (iC&G Co.). Briefly, reverse transcription
reactions were carried out in a 20  L reaction mixture contain-
ing 7  L of RT master mixture, 0.5  L of RNase inhibitor, 1  L
of RTase and 11.5  L of eluted RNA solutions. The reaction
mixture was incubated at 42℃ for 60 min, 95℃ for 5 min and
then stored at -20℃until the polymerase chain reaction (PCR).
The first PCR was carried out in a 20  L reaction mixture con-
taining 8 L  of  PCR master mixture, 0.5  L of outer primers, 2  L
of the RT reaction products and 9.5  L of distilled water. The
cycling parameters were as follows: denaturation was initiated
at 94℃for 2 min, followed by 30 cycles of 94℃for 30 sec, 60℃
for 45 sec and 65℃for 60 sec. The final extension incubation was
performed at 65℃ for 5 min. After the first PCR, 20  L of nest-
ed PCR mixture containing 8  L PCR master mixture, 0.5  L inner
primers and 11.5  L DW was added to the first PCR tube. Nested
PCR was carried out under the same conditions as the first PCR
except for the annealing temperature, which was set at 62℃. The
nested PCR products were separated on 1% agarose gels impreg-
nated with ethidium bromide (0.5  g/ mL). The DNA sequences
of MAGE primers were as follows: (MMRP1, 5′ -CTGAAGGA-
GAAGATCTGCC-3′ ; MMRP2, 5′ -CTCCAGGTAGTTTTCCT-
GCAC-3′ ; MMRP3, 5'-CTGAAGGAGAAGATCTGCCWGT-
G-3′ , W is A or T; MMRP4, 5′ -CCAGCATTTCTGCCTTTGT-
GA-3′ ).
Designing common primers for SSX 1-9 assay
The sequences of SSX 1-9 gene were obtained from National
Center for Biotechnology Information (Besthesda, MD, USA), and
the DNA homology of each SSX gene was analyzed using the
DNAsis program (Hitachi, Tokyo, Japan). The DNA sequences
that are commonly present in SSX 1-9 subtype genes that were
used for designing the common primers were as follows: (outer
sense [OS] primer, 5′ -GTGCCATGAACGGAGAYGA-3′ , Y is
C or T; outer antisense [OAS] primer, 5′ -TCTGTGGGTCCAG-
GCATGT-3′ ; inner antisense [IAS] primer 5'-TGTYTCCCCC-
TTTTGGGTCC-3′ , Y is C or T).
SSX 1-9 assay
Detection of transcripts of SSX 1-9 genes was performed using
a Cancer Hunter kit (iC&G Co.) with some modifications. In the
first and nested PCR, the common primers for SSX 1-9 gene
were used in place of common primers for MAGE 1-6. All other
procedures and temperature conditions for PCR were identical
to the MAGE 1-6 assay. 
RESULTS
Primer design and development of SSX 1-9 assay
In order to design common primers that bind to 9 SSX cDNAs
together, DNA sequences of the SSX subtypes were compared.
The SSX-1 sequence showed more than 90% DNA homology
with all other SSX subtype sequences (data not shown). Using
highly homologous DNA sequences, common primers that can
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for the SSX 1-9 assay. The binding site of common primers on
SSX-1 gene and the products amplified by the SSX1-9 assay and
the MAGE 1-6 assay are summarized in Fig. 1. All primers (OS,
OAS, and IAS) had 100% homology with the sequences of the
9 SSX cDNAs, and were used for the SSX 1-9 assay. The tran-
scripts of MAGE 1-6 genes and SSX 1-9 genes were detected in
SNU484 and AMC HN-7 cell lines, but not in normal blood cells.
The expected DNA sizes amplified by the SSX 1-9 assay and the
MAGE 1-6 assay were 490-492 bp and 448-472 bp, respectively.
Detection of the transcripts of SSX 1-9 genes in cancer
cell lines
In order to evaluate the sensitivity of the SSX 1-9 assay, mRNA
was isolated from 35 cancer cell lines described previously in this
paper, and transcripts of SSX 1-9 genes were detected by the SSX
1-9 assay. Thirty one (88.6%) of the 35 cancer cell lines were
positive (Fig. 2). All 3 head and neck cancer cell lines were pos-
itive in both gene assay (data not shown). 
Detection of the transcripts of SSX 1-9 and MAGE 1-6 in
cancer tissues
The transcripts of MAGE 1-6 and SSX 1-9 genes were detected in
24 (82.8%) and 22 (75.9%) of 29 fresh cancer tissues from head
and neck cancer patients. Eighty six percent (18/21) and 72.7%
(16/21) of squamous cell carcinoma cells expressed MAGE 1-6
genes and SSX 1-9 genes, respectively. Sixty three percent (5/8)
of other pathologic types of cancers expressed both MAGE 1-6
genes and SSX 1-9 genes (Fig. 3, Table 1).
Detection of the transcripts of SSX 1-9 and MAGE 1-6 in
sputum samples
In order to investigate the abilityof MAGE 1-6 and SSX 1-9
assays to detect small numbers of cancer cells mixed in sputum,
SNU484 (MAGE- and SSX-positive cell lines) were added to
normal sputum. After digesting the sputum with specimen pro-
tector, mRNA was isolated, and MAGE 1-6 and SSX 1-9 assays
were performed. Both assays detected transcripts in samples
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Fig. 1. The binding sites of common primers on SSX-1 cDNA (A) and PCR products amplified by MAGE 1-6 and SSX 1-9 assay (B).
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Fig. 2. Detection of SSX 1-9 transcripts of cancer cell lines by SSX 1-
9 assay. M: Marker; 1: SNU 484; 2: SNU 620; 3: SNU 638; 4: SNU 668;
5: SNU C1; 6: SNU C4; 7: SNU C5; 8: HT29; 9: HCT 116; 10: AMC-
HN3; 11: AMC-HN4; 12: AMC-HN7; 13: U937; 14: HL 60; 15: Caski;
16: C4-II; 17: ME-180; 18: Hela; 19: CUNC-6; 20: SiHa; 21: NCI-H292;
22; NCI-H522; 23: NCI-H1703; 24: A-549; 25: PC 3; 26: DU 145; 27:
HEPG2; 28: SNU 182; 29: SNU 354; 30: SNU 387; 31: SNU 398; 32:
SNU 423; 33: HEK 293; 34: MDA 231; 35: SAOS 2.
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Fig. 3. Detection of MAGE 1-6 and SSX 1-9 gene expressions in can-
cer tissue of the patients with head and neck cancer by MAGE 1-6
assay and SSX 1-9 assay.
SSX 1-9
SSX 1-9
MAGE 1-6
MAGE 1-6
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
M1 61 71 81 92 02 12 22 32 42 52 62 72 82 9containing more than 20 SNU484 cells (Fig. 4).
Eighteen samples of induced sputum from head and neck can-
cer patients and 22 samples of induced sputum from patients with
benign lung disease were collected. After digestion of sputum with
specimen protector and isolation of mRNA in liquefied sputum,
MAGE 1-6 and SSX 1-9 assays were performed. The transcripts
of MAGE 1-6 and SSX 1-9 genes were detected in 72.2% (13/18)
and 77.8% (14/18) of fresh induced sputum samples from head
and neck patients (Fig. 5, Table 2). The MAGE 1-6 assay detect-
ed transcripts in 33.3% of sputum samples from TNM stage T1
tumors, 88.9% of T2 tumors, 75% of T3 tumors and 100% of
T4 tumors. The SSX 1-9 assay detected transcripts in 100% of
sputum samples from T1 tumors, 77.8% of T2 tumors, 75% of
T3 tumors and 100% of T4 tumors (Table 3). In order to evalu-
ate the specificity of both assays, transcripts of the MAGE 1-6 and
SSX 1-9 assays in induced sputum samples from patients with
benign lung disease were detected. The MAGE 1-6 assay was
positive in 4.5% (1/22) and the SSX 1-9 assay was positive in
13.6% (3/22) of the samples (Fig. 6). These results represents
MAGE 1-6 assay is more specific than SSX 1-9 asaay.
Combination of MAGE 1-6 and SSX 1-9 assay in the
cancer tissue and induced sputa of head and neck cancer
patients
In head and neck cancer patients, the MAGE 1-6 assay was posi-
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Fig. 4. Detection of  the transcripts of MAGE 1-6 and SSX 1-9 genes in
sputum containing SNU484 by MAGE 1-6 assay and SSX 1-9 assay.
GAPDH
No. of cancer cell in
normal sputum
MAGE 1-6
SSX 1-9
01 5 2 0 1 0 0
Fig. 5. Detection of MAGE 1-6 and SSX 1-9 gene expressions in sputum
of the patients with head and neck cancer by MAGE 1-6 assay and
SSX 1-9 assay.
MAGE 1-6
MAGE 1-6
SSX 1-9
SSX 1-9
M1 234 56 78 9 1 0
M1 11 21 3 1 41 51 6 1 7 1 8
Fig. 6. Representative results of MAGE 1-6 and SSX 1-9 expression
in sputum of  the patients with benign lung disease (n=22) by MAGE
1-6 or SSX 1-9 assay.
MAGE 1-6
SSX 1-9
GAPDH
123456789 1 0 1 1 1 2
MAGE: 4.5%, SSX: 13.6%
Pathology Primary site
No. of positive reaction (%)
MAGE SSX
Table 1. Analysis of the profile of MAGE and SSX gene expression
in cancer tissue according to the pathology of head and neck
cancer
Squamous cell carcinoma Larynx (9)* 9 (100) 7 (77.8)
Nasopharynx (2) 0 (0) 2 (100)
Oropharynx (4) 3 (75) 1 (25)
Hypopharynx (2) 2 (100) 2 (100)
Oral cavity (4) 4 (100) 4 (100)
Verrucous carcinoma Larynx (1) 1 (100) 1 (100)
Undifferentiated carcinoma Nasopharynx (1) 0 (0) 1 (100)
Lymphoma Lymphatics (2) 1 (50) 1 (50)
Thyroid ca Thyroid (3) 3 (100) 2 (66.7)
Adenoid cystic carcinoma Submandibular 1 (100) 1 (100)
gland (1)
Total (n=29) 24 (82.8) 22 (75.9)
*No. of total cases tested. MAGE: melanoma antigen gene; SSX: synovial
sarcoma on X chromosome.
Pathology Primary site
No. of positive reaction (%)
MAGE SSX
Table 2. Analysis of the profile of MAGE and SSX gene expression
in sputum according to the pathology of head and neck cancer
*No. of total cases tested. MAGE: melanoma antigen gene; SSX: synovial
sarcoma on X chromosome.
Squamous cell carcinoma Larynx (12)* 8 (66.7) 9 (75)
Hypopharynx (1) 0 (0) 0 (0)
Nasopharynx (1) 1 (100) 1 (100)
Oropharynx (1) 1 (100) 1 (100)
Adenocarcinoma Hypopharynx (1) 1 (100) 1 (100)
Adenoid cystic carcinoma Oropharynx (1) 1 (100) 1 (100)
Basaloid carcinoma Oropharynx (1) 1 (100) 1 (100)
Total (n=18) 13 (72.2) 14 (77.8)tive in 82.8% of cancer tissues and 72.2% of induced sputa. The
SSX 1-9 assay was positive in 75.9% of cancer tissues and 77.8%
of induced sputa. When both MAGE 1-6 assay and SSX 1-9 assay
were performed on the same specimen, 96.6% of cancer tissues
and 94.4% of induced sputa were positive in either one of the
two assays (Table 4).
DISCUSSION
Cancer antigens that have a high frequency of expression exclu-
sively in cancer cells can be excellent markers for cancer diag-
nosis. The expression of MAGE and SSX genes are highly spe-
cific to cancer cells, but their use in the detection of a small num-
ber of cancer cells by RT-PCR has been limited by the low expres-
sion frequency of individual genes. If the transcripts of several
cancer antigen genescould be detected simultaneously by RT-PCR,
cancer detection rates could be increased. Two major methods
have been described one is multiplex PCR, which combines sev-
eral specific primers in the same reaction (12), and the other is
PCR that uses common primers that simultaneously bind to mul-
tiple targets. Whereas it is difficult to amplify more than 5 targets
using multiplex PCR, multiple targets can be detected with few
limitations by performing PCR using common primers. In a pre-
vious study, we showed that RT-nested PCR using common pri-
mers was a very useful method for detecting MAGE-expressing
cancer cells (8).
Expression analysis has demonstrated that SSX is a member of
the recently described cancer/testis antigen class. It is expressed
in a variety of different human neoplasms, but not in normal tis-
sues, with the exception of testis and a weak expression in the
thyroid. The SSX family of genes consists of several subtypes Tureci
et al. (13) studied the expression of SSX genes in 325 specimens
of human neoplasms, and found that SSX-1, -2, and -4 subtypes
are expressed in 8%, 15% and 15% of the cancers, respectively,
while the expression of the SSX-5 or SSX-3 subtypes were rare
or absent. Expression of at least one of the SSX family members
was most frequently observed in head and neck cancer (75%),
followed by ovarian cancer (50%), malignant melanoma (43%),
lymphoma (36%), colorectal cancer (27%) and breast cancer
(23%). These results suggest that simultaneous detection of tran-
scripts of multiple SSX genes by RT-nested PCR will be valuable
in the diagnosis of SSX-expressing cancer. The known SSX fami-
ly members share more than 90% homology at the DNA level.
In the present study, we designed new common primers and
developed an SSX 1-9 assay that can detect cancer cells express-
ing at least one of the 9 SSX genes. Our SSX 1-9 assay success-
fully detected the transcripts of all SSX 1-9 genes in 31 out of 35
cancer cell lines.
In order to compare the sensitivity of MAGE 1-6 and SSX 1-
9 assays, and to evaluate the value of combining both assays in
diagnosis, we detected the transcripts of MAGE and SSX genes
in 29 cancer tissue samples of head and neck cancer patients.
The MAGE 1-6 and SSX 1-9 assays were positive in 82.8% and
75.9% of cancer tissues, and 96.6% of cancer tissues were posi-
tive for at least one of the two assays. The SSX-positive rate in
head and neck cancer tissues observed in the present study is
higher than the rate reported by Tureci et al. (13). The results
from the present study show that the SSX genes, as well as the
MAGE genes, are expressed in head and neck cancer tissue, and
that combination of the MAGE 1-6 assay and the SSX 1-9 assay
can detect more than 94% of head and neck cancers.
RT-PCR-based amplification of transcripts that are expressed
in cancer cells, but not in normal non-neoplastic cells, is increas-
ingly being used as a sensitive diagnostic tool for detecting rare
disseminated or exfoliated cancer cells to improve the accuracy
of cancer staging and to aid in developing early detection pro-
tocols. In particular, detection of transcripts of cancer markers in
sputum may be very useful for cancer screening or early diagno-
sis of cancer of the respiratory tracts. In this study, we evaluat-
ed the sensitivites of MAGE 1-6 and SSX 1-9 assays in detecting
cancer cells in induced sputum of head and neck cancer patients.
It has been reported that head and neck cancer can be diagnosed
by sputum cytology (14, 15). The reports suggested that cancer
cells from head and neck malignancies can be expelled from can-
cer tissue and end up in sputum. Matsuda et al. (14) detected
29.4% of T1 lesions and 63.3% of T2 lesions of head and neck
malignancies by sputum cytology. In the present study, 33.3%
of T1 lesions (N=3) and 88.9% of T2 lesions (N=9) were detect-
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Cancer stage (N0)
No. of positive reaction (%)
MAGE SSX
Table 3. Analysis of the profile of MAGE and SSX gene expression
in sputum according to the cancer stage of head and neck cancer
MAGE: melanoma antigen gene; SSX: synovial sarcoma on X chromo-
some.
T1 (3) 1 (33.3) 3 (100)
T2 (9) 8 (88.9) 7 (77.8)
T3 (4) 9 (75) 3 (75)
T4 (1) 1 (100) 1 (100)
MAGE SSX
No. of positive reaction (%)
Tissue Sputum
Table 4. Detection of MAGE and SSX gene expression by MAGE
1-6 or SSX 1-9 assay in patients with head and neck cancer
+ and - 6 (20.7) 3 (16.7)
- and + 4 (13.8) 4 (22.2)
+ and + 18 (62.1) 10 (55.6)
- and - 1 (3.4) 1 (5.6)
+ 24 (82.8) 13 (72.2)
+ 22 (75.9) 14 (77.8)
+ or + 28 (96.6) 17 (94.4)
MAGE: melanoma antigen gene; SSX: synovial sarcoma on X chromo-
some.ed by MAGE 1-6 assay, and 100% of T1 lesions (N=3) and 77.8
% of T2 lesions (N=9) were detected by the SSX 1-9 assay. All
T1 and T2 lesions were detected by either one of the two assays,
and there was no relationship between MAGE or SSX gene expres-
sion and the tumor stage. These results suggest that it may be
possible to detect small numbers of cancer cells that express at
least one of MAGE 1-6 or SSX 1-9 genes in sputum or in malig-
nant tissue by performing the MAGE 1-6 and the SSX 1-9 assays
together. Thus the combination of these assays may become very
useful for screening or early diagnosis of primary or recurrent
head and neck cancers.
The MAGE 1-6 and SSX 1-9 gene transcripts were detected in
4.5% and 13.6% of sputum of patients with benign lung disease.
These false positive results may be due to the detection of dys-
plastic cells in sputum. One possible explanation for the false
positive amplification of MAGE or SSX transcripts is the activa-
tion of MAGE genes by dysplastic cells during early tumorigen-
esis (16). Another possible explanation is the low level of tran-
scription of MAGE or SSX genes in normal cells (17, 18). We have
been following up these patients at 3-6 month intervals some of
patients were negative for both MAGE and SSX assays during the
follow-up period, while others consistently tested positive. If the
results show continuous positive on follow up test, it is need to do
the screening work-up to rule out occult head and neck cancer.
CONCLUSION
We developed an SSX 1-9 assay to detect the transcripts and of
9 SSX genes simultaneously, and investigated the usefulness of
SSX 1-9 MAGE 1-6 assays in the detection of cancer cells in tis-
sue and sputum samples of head and neck cancer patients. The
results of the present investigation suggest that the combination
of MAGE 1-6 and SSX 1-9 assays may be a sensitive diagnostic
tool in detecting small numbers of malignant cells in the cancer
tissue and induced sputum of head and neck cancer patients.
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